UKâs MHRA Accepts Biospliceâs Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (âBiospliceâ), a late-stage biopharmaceutical company developing lorecivivint (âLORâ), a first-in-class small-molecule inhibitor of CLK/DYRK kinases, for...